Measuring circulating miRNAs: The new "PSA" for breast cancer?

Oncologist

Volumn 15, Issue 7, 2010, Pages 656-

  Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 155; MICRORNA 195; MICRORNA LET 7A; UNCLASSIFIED DRUG;

BLOOD ANALYSIS; BREAST CANCER; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EDITORIAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956115196     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0176     Document Type: Editorial

References (4)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-854.
2. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006;25:6170-6175.
3. Ross JS, Carlson JA, Brock G. miRNA: The new gene silencer. Am J Clin Pathol 2007;128:830-836.
4. Heneghan HM, Miller N, Kelly R et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The Oncologist 2010;15: 673-682.